GlassScriptPhysician profile
Michael S Flowers
NPI 1922540756
$1,111.39
in general payments reported to CMS, 2019-2025
14 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.22 · 2022: $124 · 2023: $288 · 2024: $195 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.16 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $271.32 | 2022-2025 | |
| Cranial Technologies, INC | $199.51 | 2022-2025 | Doc Band |
| Sanofi Pasteur INC. | $132.15 | 2022-2025 | |
| Glaxosmithkline, LLC. | $112.12 | 2021-2025 | Bexsero, Penmenvy |
| Alk-Abello, INC | $96.67 | 2023-2025 | Neffy, Ragwitek, Odactra |
| Merck Sharp & Dohme LLC | $66.88 | 2022-2025 | Gardasil 9, M-M-R II, Vaxneuvance |
| Phadia US INC. | $55.62 | 2022-2025 | Immunocap |
| Seqirus USA INC | $46.35 | 2022-2025 | Flucelvax |
| Corium, LLC | $44.02 | 2023 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $23.49 | 2023 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $21.96 | 2025 | |
| Tris Pharma INC | $14.19 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $13.60 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $13.51 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.